Table 5. Treatments received by patients during the follow-up period.
| Overall | No mechanical ventilation | Mechanical ventilation | P Value | |
|---|---|---|---|---|
| n | 145 | 109 | 36 | |
| Any SARS-CoV-2 treatment (n, %) | 97 (66.9) | 63 (57.8) | 34 (94.4) | <0.001 |
| Protease inhibitor (n, %) | 86 (59.3) | 55 (50.5) | 31 (86.1) | <0.001 |
| Hydroxychloroquine (n, %) | 70 (48.3) | 45 (41.3) | 25 (69.4) | 0.006 |
| Remdesivir (n, %) | 16 (11.0) | 0 (0.0) | 16 (44.4) | <0.001 |
| Tocilizumab (n, %) | 17 (11.7) | 3 (2.8) | 14 (38.9) | <0.001 |
| Any antibiotic treatment (n, %) | 56 (38.6) | 25 (22.9) | 31 (86.1) | <0.001 |